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Introduction: The trend of prescribing VD preparations for nonspecific body aches and self-medication has
increased significantly. The importance of vitamin D toxicity (VDT) has been underestimated and under
recognized. This study was done to determine the frequency toxicity (>150 ng/ml) in subjects for 25-hydroxy
vitamin D (25OHD) and evaluate the vitamin D (VD) supplements used by these subjects.
Methodology: This descriptive cross-sectional study was conducted at the Section of Chemical Pathology, Aga
Khan University Hospital Karachi from April 2020 to March 2021. Subjects with 25OHD toxicity were contacted
and information related to history of calcium and VD supplementation were collected. The statistical analysis
was performed using the Microsoft Excel 2016.
Results: Over a year period 105398 subjects were tested for serum 25OHD, of which 0.34% (n = 364) subjects had
25OHD level of >150 ng/ml. After satisfying exclusion criteria 186 subjects (78 were <18 years of age and 108
were adults) were included in final analysis. All of these were using VD supplements and the main indications
were delayed growth/short height (43.7%, n = 34) and aches or pains in (54.6%, n = 59) in pediatric and adult
subjects respectively.
Most of the subjects were taking supplements orally (74.1%, n = 138). Commonly prescribed preparation in
adults and pediatric was 200,000 IU (70.4%, n = 76) and 400 IU (35.9%, n = 28) respectively. Most subjects took
supplements for 1–3 months (68.3%, n = 127). Stated total supplementation ranged from 20,000 IU to 3600,000
IU in pediatric subjects and 200,000 IU to 96,00,000 IU in adults.
Conclusions: Supplementation is a leading cause of potential toxic levels of 25OHD. The condition can be pre
vented by careful use of VD supplements and consistent monitoring.

1. Introduction
High prevalence of vitamin D deficiency (VDD) is well recognized in
Pakistan and globally [1]. Strategies and recommendations to combat
VDD have been put forward but there is wide variation and no consensus
on any one strategy [2,3]. Hence, Practice patterns of physicians in
treating VDD vary due to lack of clear guidelines on optimal dosing
regimen and availability of different vitamin D (VD) preparations.
Replacement of VD for maintaining sufficient bone health is necessary
but achieving balance between optimal and toxic levels is equally
important. For this serum 25-hydroxy VD (25OHD) testing is recom
mended to adjust dose accordingly. International Osteoporosis Foun
dation recommends measuring serum 25OHD levels after 2–3 months of

VD replacement (3). However very few physicians perform biochemical
testing to assess the status of 25OHD prior to or after VD replacement
[4].
The trend of prescribing VD preparations for nonspecific body aches
in VD deficient endemic areas and self-medication with over the counter
VD supplements has increased significantly [5,6]. According to studies,
serum 25OHD levels above 150 ng/ml are considered toxic levels [7–9].
Self and prescribed supplementation or errors of labeling of VD formu
lations, or inadvertent use such administration of high doses of VD in
infants or children for complaints such as delayed teething, ‘late
walking’, and ‘knock-kneed gait’ are reported [10].
The importance of vitamin D toxicity (VDT) has been underestimated
and under recognized. This study was done to determine the frequency

; VDT, Vitamin D toxicity; 25OHD, 25-hydroxyvitamin D; VD, Vitamin D; VDD, Vitamin D deficiency; IM, IntramuscularI.
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of subjects identified with 25OHD toxicity (>150 ng/ml) and evaluate
the VD supplements used by these subjects.

4.0–150 ng/ml. Two-level quality control materials were run with each
batch of samples for internal quality control. External proficiency was
assured by analyzing samples from the College of American Pathologists
thrice per year, throughout the study period, and all external proficiency
surveys during the study period were acceptable. The following refer
ence ranges were used and relate to 25OHD levels: Deficient <20 ng/
mL, insufficient 21–29 ng/mL, sufficient/adequate 30–100 ng/mL, high
or hypervitaminosis D > 100 ng/mL, toxicity >150 ng/mL (2, 8).

2. Material and methods
This prospective cross-sectional study was conducted at the Section
of Chemical Pathology, Department of Pathology and Laboratory Med
icine, AKUH Karachi Pakistan after approval from Aga Khan University
Hospital’s Ethics Review Committee (ERC ID: 2019-1973-6924). Data of
subjects tested for serum 25OHD between April 2020 to March 2021 was
reviewed daily and those with 25OHD levels >150 ng/ml were con
tacted via telephone. Only the initial results of the subjects tested at
Clinical Laboratory were included. Those with incomplete clinical his
tory, 25OHD levels <150 ng/ml, whose contact numbers were unavai
lable or not answering telephone calls were excluded. To maintain
confidentiality all identifiers were removed, and study identity numbers
were generated. The work has been reported in line with the STROCSS
criteria [11].
After explaining the reason for phone call, verbal informed consent
was taken and clinical information of calcium and VD supplementation
including prescribed or self–medicated, indications for prescription,
formulation strength, total dosage, frequency, duration, and calcium
status was collected on a structured clinical history forms. The hyper
calcemia was labeled when serum calcium was >10.2 mg/dl.

4. Data analysis
The statistical analysis was performed using the Microsoft Excel
2016. Subjects were categorized into two age groups: <18 years (pedi
atric) and ≥18 years (adult). Total doses of VD supplements were added
to calculate cumulative supplementation and daily supplementation was
calculated by dividing cumulative dose by duration of supplementation.
Descriptive statistics median (interquartile range, IQR) were calcu
lated for numerical data while frequency (percentage) for categorical
data. Frequencies of subjects with VD toxicity were derived and their
correlates were evaluated in the both the age groups. Demographics (age
and gender), calcium status of subjects, indications, formulation
strengths, frequency, duration, cumulative and daily dose of supple
mentation were generated.
5. Results

3. Biochemical analysis

During one-year period 105,398 subjects were tested for serum
25OHD levels at Clinical Laboratories. Fig. 1 shows the distribution of
subjects tested for 25OHD. Toxicity was observed in 0.34% (n = 364)
subjects. Of these 186 subjects (78 pediatric and 108 adults) were

Serum 25OHD levels were analyzed on Liaison immunoassay
analyzer (DiaSorin Inc. Diagnostics, USA) using chemiluminescence
immunoassay technique. The assay’s analytical measurement range was

Fig. 1. Consort showing distribution of subjects tested for VD from April 2020 to March 2021 at AKUH clinical laboratories.
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included in final analysis with 63% (n = 117) being female.
In 90% (n = 167) subjects [92% (n = 72) pediatric and 88% (n = 95)
adults] VD supplement was prescribed by physician. Table 1 shows the
demographics, indications for testing and available calcium status of the
subjects. The main indications for taking VD supplements in pediatric
population were delayed growth/short height (43.7%m, n = 34), VDD
(24.4%, n = 19) and delayed walking/milestones (19.2%, n = 15). In
contrast, the main indications in adults were aches/pains (54.6%, n =
59) and VDD in (32.4%, n = 35) of subjects. Serum calcium levels were
available for 34% (n = 63) subjects with median calcium levels of 9.75
(0.9) mg/dl.
Table 2 shows details on VD supplementation regarding dose,
formulation types, route and duration. Majority subjects used oral sup
plements with different formulation strengths of VD ranging from 400
IU to 600,000 IU. In adults, 70.6% (n = 76) were taking 200,000 IU oral,
14.8% (n = 16) took 600,000 IU, intramuscularly. While in pediatric
subjects 35.9% (n = 28) were taking 400 IU/drop, (ranging from 1 to 10
drops per day) and 11.5% (n = 9) subjects were taking 200,000 IU/ml
(6,666 IU/drop) and number of drops ranged from 1 to 2 drops per day.
Stated total supplementation ranged from 20,000 IU to 3600,000 IU in
pediatric subjects, which was calculated to range from 400 IU to 28,571
IU/day. While 200,000 IU to 96, 00,000 IU in adults is calculated to
range from 2,000 IU to 200,000 IU (Table 2). Duration of supplemen
tation varied from 1 week to years with majority taking supplementation
for 2–3 months (Table 2).

Table 2
Details of VD supplementation in subjects with 25 (OH)D levels >150 ng/ml.

Cumulative and daily
supplementation

VD supplementation
route
VD supplementation
strengths used (IU)

Duration of VD
supplementation

6. Discussion
In 1970s, VD was central to eradication of rickets and osteomalacia.
However, identification of vitamin D receptors in many organs and tis
sues in the body linked VDD to a variety of outcomes. Together with
greater public interest and increased cognizance about benefits of VD
resulted in VD becoming a popular supplement and one of the most
common over the counter medicines nowadays [12]. Many of the sup
plements are in the form of unregulated formulations dispensed with
little guidance for safe administration. VD is not a benign drug and
excessive supplementation can lead to serious complications and hos
pitalization. Khan MN et al. evaluated the causes of hypercalcemia other
than solid tumour malignancy and found out that 17.3% (n = 25) pa
tients had hypercalcemia due to VDT [13]. A paradigm shift from VDD
to a global increase in cases of VDT is been noted. A decade-long

Demographics
Indications for VD
Supplementation

Calcium Status of
Subjects

Male
Female
Age (Years)
VD Deficiency (<20
ng/dl) n (%)
Bone Pain n (%)
Delayed Growth/Short
Height n (%)
Delayed Walking/
Milestones n (%)
Renal insufficiency n
(%)
Bowing of Legs n (%)
COVID = 19 n (%)
Others n (%)
Normal Calcium levels
Calcium (mg/dl)
Hypercalcemia
Calcium (mg/dl)

>18 Years
n = 108

36 (46.2%)
42 (53.8%)
2.0 (3.9)
19 (24.4%)

33 (30.6%)
75 (69.4%)
41.4 (27.4)
35 (32.4%)

3 (3.8%)
34 (43.7%)

59 (54.6%)
–

15 (19.2%)

–

–

6 (5.6%)

3 (3.8%)
–
4 (5.1%)
20 (76.9%)
9.6 (0.5)
6 (23.1%)
10.9 (0.32)

–
4 (3.7%)
4 (3.7%)
26 (70.3%)
9.7 (0.5)
11 (29.7%)
12.1 (2.5)

>18 Years n
= 108

4,20,000
(600,000)

16,00,000
(14,00,000)

12,066
(18,300)

27,066
(15,238)

64 (82.1%)
10 (12.8%)
4 (5.1%)
28 (35.9%)
9 (11.5%)
–
–
–
–
–
24 (30.8%)
5 (6.5%)
12 (15.3%)
8 (10.3%)

74 (68.5%)
24 (22.2%)
10 (9.3%)
–
–
1 (0.9%)
1 (0.9%)
2 (1.9%)
1 (0.9%)
5 (4.6%)
76 (70.4%)
16 (14.8%)
6 (5.6%)
–

3 (3.8%)
1 (1.2%)
–
–
–
6 (7.7%)
22 (28.2%)
33 (42.3%)
8 (10.3%)
3 (3.8%)
6 (7.7%)

–
–
1 (0.9%)
2 (1.9%)
3 (2.8%)
2 (1.8%)
14 (12.9%)
58 (53.8%)
15 (13.9%)
6 (5.6%)
13 (12%)

IQR= Interquartile range, VD= Vitamin D, IM= Intramuscular.

observational on data (unpublished) from our laboratory showed
increasing number of individuals with elevated serum 25OHD levels
with increase in number of request for 25OHD testing. The prevalence of
potential VDT in our study was 1.12% in pediatric subjects and 0.23%
adult subjects (Fig. 1).
Contextual guidelines on appropriate VD replacement are lacking,
leading to varied prescribing practices among physicians, aggressive
replacement of VD and increased risk of VDT [13,14]. The Institute of
Medicine’s report and The Endocrine Society guidelines in 2011 sug
gested that higher levels of 2000, 4000 and 10000 IU/day for infants,
children and adults respectively may be needed to correct VDD [2,15].
However, in this study median daily dose was much higher than the
recommended dose in both pediatrics age group (12,066 IU/day) and
adults (27,066 IU/day). Caglar A et al. cited similar findings in 38
hospitalized children diagnosed with VDT during a 5-year study period
[16]. All children were taking vitamin D supplements with the median
dose of 1,200,000 IU. Nine of these used supplements for delayed
teething and late walking. Misgar RA et al. reported VDT in 32 adults
with hypercalcemia in 3-year prospective study [14]. The main indica
tion for supplementation were aches and pain (n = 22) and none of the
patients had prior 25OHD testing neither was subjected to biochemical
monitoring. Similarly, the diagnosis of rickets, osteomalacia, osteopo
rosis or VDD by serum 25OHD level testing was also not determined in
most of the subjects in the present study prior to prescribing VD.
In the present study, although most of the subjects had an initial
prescription from the physician. It is likely that the key components of a
prescription like formulation strength, dosage, duration and follow-up
were either not properly highlighted in prescription or not followed
by subjects. This is evidenced by the increased dosage (3–10 drops)
taken by a 22% (n = 17) children out of the total 28 children who were
prescribed 1–2 VD drops/day. Out of these 17 children, three developed
hypercalcemia. Bilbao et al. described similar cases of two infants who

Table 1
Characteristics of Pediatric (<18 years) and Adult (>18 years) subjects tested at
AKUH clinical laboratories with indications of VD supplementation.
<18 Years
n = 78

Total Cumulative VD
Supplements taken (I.
U) Median (IQR)
VD Supplements
Taken per day Median
(IQR)
Oral
Intramuscular
Both (Oral & IM)
400/drop
6,666/drop
5,000
10,000
20,000
40,000
50,000
200,000
600,000
Combination
200,000
400
þ
600,000þ
400
6666
10,000
50,000
200,000
Once
1 month
2–3 months
4–6 months
7–12 months
>1 year

<18 Years
n = 78

IQR= Interquartile range, VD= Vitamin D, COVID-19 = Coronavirus Disease
2019, Median (IQR) was reported for age, and calcium levels.
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developed hypercalcemia after receiving over-the-counter vitamin D
supplementation far above the recommended dose [17].
In this study, it was identified that large doses of supplements were
continuously taken for months and years without monitoring of serum
25 (OH) D levels in contrast to the recommendations by Endocrine so
ciety to monitor 25OHD levels after 2–3 months of prescribing VD
supplements (Supplemental Table 1 a & b). An adult subject was taking
5000 IU/day for more than 5 years without monitoring of 25OHD levels.
Another subject took intramuscular (IM) injections of 200,000 IU on
alternate days for 2 weeks along with 200,000 oral capsules once a week
for 5 years. A pediatric subject was taking 200,000 IU oral supplements
once a week for more than a year. and details are mentioned in Sup
plemental Table 1 a & b.
In Pakistan, two preparations of 10 ml oral drops of VD are available,
one with 400 IU/drop and other with 200,000 IU/ml or 6666 IU/drop
(Counting 30 drops in the 1 ml dropper), which is 16-fold higher than
400 IU. Nine (11.5%) children were receiving two drops daily (cumu
lative dose 13,332 daily) and two of them developed hypercalcemia.
Raj Kumar K et al. reported similar case of dosing error with overthe-counter VD supplement in a 3 month-old Asian-American infant
who was prescribed 400 IU once daily [18]. Initially parents were
administering 1 mL daily of 400 IU/mL infant vitamin D solution. But
after sometime they replaced 400 IU/mL infant vitamin D solution with
a new brand of infant vitamin D liquid preparation which provided 400
IU of vitamin D per drop. Without noticing the difference in the con
centrations between the two preparations, the parents were giving the
infant 1 mL daily of the new preparation. So the infant was receiving a
30-fold overdose of vitamin D (12,000 IU) daily. In our study, one pe
diatric subject accidently took 10 ml bottle of VD drops (400IU/drop) in
one go and developed hypercalcemia.
The VDT has a varied presentation ranging from asymptomatic to
acute life threatening complications mainly due to hypercalcemia. In
our study, eleven adults developed hypercalcemia {median calcium
levels 10.7 mg/dl (0.2)}, out of these six were hospitalized. Pandita KK
et al. reported 15 cases of hypervitaminosis D with hypercalcemia, 12
had evidence of renal dysfunction with median creatinine level of 2.1
mg/dl [19]. Genzen JR et al. reported 25OHD levels of >150 ng/ml in
[n = 15 (~0.03%)] and [n = 27 (~0.05%)] patients with hypercalcemia
in 4 and 2 patients from Weill Cornell Medical College/New York
Presbyterian Hospital and University of Iowa Hospitals and Clinics
respectively [20]. Masood et al. in a prospective intervention study in
ambulatory care setting, 100 subjects with VDD were randomized to
receive a dose of 600,000 or 200,000 IU of Cholecalciferol via an oral or
IM route and serum 25OHD measures at 2, 4 and 6 months after the
intervention showed that VDD was corrected in 70.6–93.85% of par
ticipants and the mean levels remained significantly higher from base
line in all groups at all-time points during the 6 months of observation
[21]. Basit et al. used a single IM dose of 600,000 IU of vitamin D3 for
the treatment of painful diabetic neuropathy and reported significant
increase in vitamin D and calcium levels in patients at 20 weeks [22].

with the available preparations.
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